Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.
Quote | Semper Paratus Acquisition Corporation Unit (NASDAQ:LGSTU)
Last: | $6.10 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $6.10 |
High: | $0 |
Low: | $0 |
Volume: | 38 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Semper Paratus Acquisition Corporation Unit (NASDAQ:LGSTU)
Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations. WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding...
New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW, LGSTU), a publicly-traded special purpose acquisition company, announced today that its shareholders have approved the proposed business combination (the...
Message Board Posts | Semper Paratus Acquisition Corporation Unit (NASDAQ:LGSTU)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Semper Paratus Acquisition Corporation Unit Company Name:
LGSTU Stock Symbol:
NASDAQ Market:
Semper Paratus Acquisition Corporation Unit Website:
Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations. WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holding...
New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW, LGSTU), a publicly-traded special purpose acquisition company, announced today that its shareholders have approved the proposed business combination (the...
New York, NY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced that it has filed a supplement (“Prospectus Supplement”) to its defin...